

Product datasheet for TP727832

Human Recombinant Protein

Product data:

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product Type:	Recombinant Proteins
Description:	Recombinant Human ENPP-2/LysoPLD (C-6His)
Species:	Human
Expression cDNA Clone or AA Sequence:	Ala36-Ile863
Tag:	C-His
Buffer:	Lyophilized from a 0.2 um filtered solution of 20mMPB,150mMNaCl,pH7.4.
Note:	Recombinant Human Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 is produced by our Mammalian expression system and the target gene encoding Ala36-Ile863 is expressed with a 6His tag at the C-terminus.
Storage:	Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Stability:	12 months from date of despatch
Synonyms:	ATX; ATXFLJ26803; ATX-X; Autotaxin; autotaxin-t; EC 3.1.4.39; ectonucleotide pyrophosphatase/phosphodiesterase 2;E-NPP 2; ENPP2; LysoPLD; NPP2; PD-IALPHA; PDNP2; PDNP2NPP2
Summary:	ENPP-2, also known as Autotaxin, belongs to the ectonucleotide pyrophosphatase/phosphodiesterase (NPP) family. Some NPPs hydrolyze phosphates from nucleotides and their derivatives. ENPP-2 shares 40 - 50% identity to ENPP1 & 3, all of which contain a N-terminal intracellular domain, a single transmembrane domain and a large extracellular domain that includes a catalytic domain, two somatomedin-B-like domains, and a C-terminal nuclease-like domain.Evidence shows LPA and sphingosine 1-phosphate to be specific inhibitors of ENPP-2. ENPP-2 was originally found to stimulate tumor cell motility and has since been found to enhance tumor invasion and metastasis and to be up-regulated in several types of carcinomas including breast and lung.



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2024 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US